| Company Announcements: (reported by the Company) |
No items found
|
| Elevator Pitch: | Viral respiratory illnesses in children are frequent and costly up to $50M AUD annually with the most common identified cause, Respiratory Syncytial Virus (RSV) has no proven therapeutics or vaccines. MISTI will offer a nebuliser that is a first-in-class, low-cost, scientifically validated lung delivery system to offer rapid protection. |
| Category: | Hardware & devices, Health & biotech |
| URL: | https://www.misti.com.au/ |
| Operational Status: | Active |
| ASX Listing Code (if applicable): | |
| Year of Commencement: | 2022 |
| Address: | Melbourne, Victoria AU |
| State: | Victoria |
| Overseas Operations: | No |
| Twitter: | [twitter-timeline username=”“] |
| Facebook: | |
| Linkedin: | https://linkedin.com/company/mistiau |
| Founders: | |
| Awards won: | |
